# Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL

> **NCT02784834** · PHASE1 · TERMINATED · sponsor: **Michael Choi** · enrollment: 2 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** dimethyl fumarate

## Key facts

- **NCT ID:** NCT02784834
- **Lead sponsor:** Michael Choi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2019-02
- **Final completion:** 2019-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** lack of funding
- **Last updated:** 2019-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02784834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02784834, "Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02784834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*